Literature DB >> 26401476

Clinical and Radiologic Outcome of Gamma Knife Radiosurgery on Nonfunctioning Pituitary Adenomas.

Shyamal C Bir1, Richard D Murray1, Sudheer Ambekar1, Papireddy Bollam1, Anil Nanda1.   

Abstract

Objective To elucidate the role of Gamma Knife radiosurgery (GKRS) in the management of nonfunctioning pituitary adenomas (NFAs). Materials and Methods A retrospective review of 57 consecutive patients spanning 2000 to 2013 with NFAs was performed. Of 57 patients, 53 patients had recurrent or residual tumors after microsurgical resection. The study population was evaluated clinically and radiographically after GKRS treatment. The median follow-up time was 45.57 months. Results GKRS in pituitary adenomas showed significant variations in tumor growth control (decreased in 32 patients [56.1%], arrested growth in 21 patients [36.1%], and increased tumor size in 4 patients [7%]). Progression-free survival after GKRS at 3, 7, and 10 years was 100%, 98%, and 90%, respectively. The neurologic signs and symptoms were significantly improved after GKRS (14% versus 107%) compared with pretreated signs and symptoms (p < 0.0001). Five patients (8.8%) required additional treatment. Conclusion Recent follow-up revealed that GKRS offers a high rate of tumor control and preservation of neurologic functions in both new and recurrent patients with NFAs. Thus GKRS is an effective treatment option for recurrent and residual as well as newly diagnosed patients with NFAs.

Entities:  

Keywords:  Gamma Knife surgery; clinical and radiologic outcome; nonfunctioning pituitary adenomas

Year:  2015        PMID: 26401476      PMCID: PMC4569497          DOI: 10.1055/s-0035-1549309

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  38 in total

1.  Preservation of visual fields after peri-sellar gamma-knife radiosurgery.

Authors:  R Ove; S Kelman; P P Amin; L S Chin
Journal:  Int J Cancer       Date:  2000-12-20       Impact factor: 7.396

2.  Early palliation of oculomotor nerve palsy following gamma knife radiosurgery for pituitary adenoma.

Authors:  Takumi Abe; Masaaki Yamamoto; Matsuo Taniyama; Daisuke Tanioka; Hitoshi Izumiyama; Kiyoshi Matsumoto
Journal:  Eur Neurol       Date:  2002       Impact factor: 1.710

3.  Initial Gamma Knife radiosurgery for nonfunctioning pituitary adenomas.

Authors:  Cheng-Chia Lee; Hideyuki Kano; Huai-Che Yang; Zhiyuan Xu; Chun-Po Yen; Wen-Yuh Chung; David Hung-Chi Pan; L Dade Lunsford; Jason P Sheehan
Journal:  J Neurosurg       Date:  2014-01-03       Impact factor: 5.115

4.  Long-term outcomes after gamma knife stereotactic radiosurgery for nonfunctional pituitary adenomas.

Authors:  Kyung-Jae Park; Hideyuki Kano; Phillip V Parry; Ajay Niranjan; John C Flickinger; L Dade Lunsford; Douglas Kondziolka
Journal:  Neurosurgery       Date:  2011-12       Impact factor: 4.654

5.  Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years.

Authors:  G Minniti; D Traish; S Ashley; A Gonsalves; M Brada
Journal:  J Clin Endocrinol Metab       Date:  2004-11-23       Impact factor: 5.958

6.  Hypopituitarism following external radiotherapy for pituitary tumours in adults.

Authors:  M D Littley; S M Shalet; C G Beardwell; S R Ahmed; G Applegate; M L Sutton
Journal:  Q J Med       Date:  1989-02

7.  Low-dose Gamma Knife surgery for nonfunctioning pituitary adenomas.

Authors:  Amr M N El-Shehaby; Wael A Reda; Sameh R Tawadros; Khaled M Abdel Karim
Journal:  J Neurosurg       Date:  2012-12       Impact factor: 5.115

8.  Transsphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results.

Authors:  I Ciric; M Mikhael; T Stafford; L Lawson; R Garces
Journal:  J Neurosurg       Date:  1983-09       Impact factor: 5.115

9.  Radiation sensitivity of visual and oculomotor pathways.

Authors:  K A Leber; J Berglöff; G Langmann; M Mokry; O Schröttner; G Pendl
Journal:  Stereotact Funct Neurosurg       Date:  1995       Impact factor: 1.875

10.  Four years' experiences in the treatment of pituitary adenomas with gamma knife radiosurgery.

Authors:  Y L Lim; W Leem; T S Kim; B A Rhee; G K Kim
Journal:  Stereotact Funct Neurosurg       Date:  1998-10       Impact factor: 1.875

View more
  7 in total

Review 1.  Target delineation and optimal radiosurgical dose for pituitary tumors.

Authors:  Giuseppe Minniti; Mattia Falchetto Osti; Maximillian Niyazi
Journal:  Radiat Oncol       Date:  2016-10-11       Impact factor: 3.481

2.  Long-term hormonal and imaging outcomes of adjunctive gamma knife radiosurgery in non-functioning pituitary adenomas: a single center experience.

Authors:  Aasim N Maldar; Sanjeev Pattankar; Basant K Misra; Phulrenu H Chauhan; Milind Sankhe; Ketan Desai; N F Shah
Journal:  J Neurooncol       Date:  2022-05-20       Impact factor: 4.130

Review 3.  Epidemiology of Male Hypogonadism.

Authors:  Arthi Thirumalai; Bradley D Anawalt
Journal:  Endocrinol Metab Clin North Am       Date:  2022-02-08       Impact factor: 4.748

Review 4.  Management of nonfunctioning pituitary tumors: radiotherapy.

Authors:  Giuseppe Minniti; John Flickinger; Barbara Tolu; Sergio Paolini
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 5.  Ischemic stroke after radiation therapy for pituitary adenomas: a systematic review.

Authors:  A van Westrhenen; I S Muskens; J J C Verhoeff; T R S Smith; M L D Broekman
Journal:  J Neurooncol       Date:  2017-06-28       Impact factor: 4.130

6.  Long-term results of Gamma Knife Radiosurgery for Postsurgical residual or recurrent nonfunctioning Pituitary Adenomas.

Authors:  Yinhui Deng; Yanli Li; Xi Li; Lisha Wu; Tingting Quan; Chao Peng; Junyi Fu; Xin Yang; Jinxiu Yu
Journal:  Int J Med Sci       Date:  2020-06-18       Impact factor: 3.738

7.  Characteristic of Tumor Regrowth After Gamma Knife Radiosurgery and Outcomes of Repeat Gamma Knife Radiosurgery in Nonfunctioning Pituitary Adenomas.

Authors:  Yanli Li; Lisha Wu; Tingting Quan; Junyi Fu; Linhui Cao; Xi Li; Shunyao Liang; Minyi Huang; Yinhui Deng; Jinxiu Yu
Journal:  Front Oncol       Date:  2021-03-05       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.